Archives: Search / 2021 / 2020 / 2019 / 2018 / 2017 / 2016 / 2015
- New Marginal Zone Arm of TIDAL Study Intended to Support Accelerated Approval Application with the U.S. Food and Drug Administration -
|
Jun 4, 2021 -- Event Scheduled for Thursday, June 10, 2021 at 12:00 PM Eastern Time Featuring Deepa Jagadeesh, M.D. --
|
-Zandelisib, an investigational agent, +/- rituximab demonstrated 82% overall response rate in patients with relapsed or refractory (r/r) follicular lymphoma (FL) who had progression of disease within 24 months of first line chemoimmunotherapy (POD24); overall response rate of 93% in non-POD24-
|
May 6, 2021 -Topline TIDAL Study Data Evaluating Zandelisib in Relapsed or Refractory Follicular Lymphoma on Track to be Reported in the Fourth Quarter-
|
Apr 13, 2021 Topline TIDAL Study Data on Track to be Reported in the Fourth Quarter
|
Apr 10, 2021 Data Featured in Poster at American Association for Cancer Research Annual Meeting 2021
|
Feb 4, 2021 --Multiple Clinical Development Milestones Anticipated in 2021--
|
Jan 4, 2021 - Safety Review Committee approved Phase 1b expansion cohorts in study arm evaluating zandelisib in combination with zanubrutinib in various B-cell maligniancies -
|
Nov 10, 2020 --Expands Clinical Development of Zandelisib to New Indications and Earlier Lines of Treatment--
|
